Ignet

Gene Information

Gene symbol: DLL1

Gene name: delta-like 1 (Drosophila)

HGNC ID: 2908

Related Genes

#	Gene Symbol	Number of hits
1	C6orf208	1 hits
2	C6orf70	1 hits
3	CCR6	1 hits
4	CD59	1 hits
5	DLL4	1 hits
6	FAM120B	1 hits
7	INS	1 hits
8	NEUROG3	1 hits
9	OPRD1	1 hits
10	OPRK1	1 hits
11	OPRM1	1 hits
12	PDCD2	1 hits
13	PHF10	1 hits
14	POMC	1 hits
15	PSENEN	1 hits
16	PSMB1	1 hits
17	SST	1 hits
18	SYP	1 hits
19	TBP	1 hits

Related Sentences

#	PMID	Sentence
1	6881339	Administration of hydrocortisone to normal fed rats increased renal net glucose release from 0.93 +/- 0.25 to 2.27 +/- 0.21 mg . dl-1 . min-1 and increased its contribution to blood glucose from 27.0 +/- 4.5 to 46.6 +/- 4.0%.
2	6881339	The renal net glucose release and its contribution to blood glucose in adrenalectomized rats were 0.40 +/- 0.06 mg . dl-1 . min-1 and 16.3 +/- 1.4%, respectively, significantly less than those of normal control rats, and these parameters were raised to the levels of normal control rats by the administration of hydrocortisone.
3	6881339	In rats with streptozotocin-induced diabetes, the renal net glucose release and its contribution to blood glucose were significantly increased to 2.22 +/- 0.51 mg . dl-1 . min-1 and 46.7 +/- 4.9%, respectively, and these parameters were normalized by adrenalectomy.
4	6881339	Administration of hydrocortisone to normal fed rats increased renal net glucose release from 0.93 +/- 0.25 to 2.27 +/- 0.21 mg . dl-1 . min-1 and increased its contribution to blood glucose from 27.0 +/- 4.5 to 46.6 +/- 4.0%.
5	6881339	The renal net glucose release and its contribution to blood glucose in adrenalectomized rats were 0.40 +/- 0.06 mg . dl-1 . min-1 and 16.3 +/- 1.4%, respectively, significantly less than those of normal control rats, and these parameters were raised to the levels of normal control rats by the administration of hydrocortisone.
6	6881339	In rats with streptozotocin-induced diabetes, the renal net glucose release and its contribution to blood glucose were significantly increased to 2.22 +/- 0.51 mg . dl-1 . min-1 and 46.7 +/- 4.9%, respectively, and these parameters were normalized by adrenalectomy.
7	6881339	Administration of hydrocortisone to normal fed rats increased renal net glucose release from 0.93 +/- 0.25 to 2.27 +/- 0.21 mg . dl-1 . min-1 and increased its contribution to blood glucose from 27.0 +/- 4.5 to 46.6 +/- 4.0%.
8	6881339	The renal net glucose release and its contribution to blood glucose in adrenalectomized rats were 0.40 +/- 0.06 mg . dl-1 . min-1 and 16.3 +/- 1.4%, respectively, significantly less than those of normal control rats, and these parameters were raised to the levels of normal control rats by the administration of hydrocortisone.
9	6881339	In rats with streptozotocin-induced diabetes, the renal net glucose release and its contribution to blood glucose were significantly increased to 2.22 +/- 0.51 mg . dl-1 . min-1 and 46.7 +/- 4.9%, respectively, and these parameters were normalized by adrenalectomy.
10	7816344	Spontaneous locomotor activity in diabetic mice was also reduced by pretreatment with naltrindole, a selective delta-opioid receptor antagonist, and 7-benzylidenenaltrexone, a selective delta1-opioid receptor antagonist.
11	9178652	To examine the role of supraspinal and/or spinal endogenous delta1-opioid receptors in inhibiting the formalin-induced nociceptive response in diabetic mice, we assessed the effect of 7-benzylidenenaltrexone, a selective delta1-opioid receptor antagonist, and naltriben, a selective delta2-opioid receptor antagonist, administered either i.c.v. or i.t., on the formalin-induced flinching response.
12	9178652	These results suggest that a spinal delta1-opioid receptor-mediated endogenous antinociceptive system may inhibit the formalin-induced second phase of the nociceptive response in diabetic mice.
13	9178652	To examine the role of supraspinal and/or spinal endogenous delta1-opioid receptors in inhibiting the formalin-induced nociceptive response in diabetic mice, we assessed the effect of 7-benzylidenenaltrexone, a selective delta1-opioid receptor antagonist, and naltriben, a selective delta2-opioid receptor antagonist, administered either i.c.v. or i.t., on the formalin-induced flinching response.
14	9178652	These results suggest that a spinal delta1-opioid receptor-mediated endogenous antinociceptive system may inhibit the formalin-induced second phase of the nociceptive response in diabetic mice.
15	9430407	The morphine (5 mg/kg)-induced place preference in both diabetic and non-diabetic mice was significantly antagonized by pretreatment with beta-funaltrexamine, a selective mu-opioid receptor antagonist, but not with naloxonazine, a selective mu1-opioid receptor antagonist.
16	9430407	The morphine (5 mg/kg)-induced place preference in non-diabetic mice was attenuated by pretreatment with either naltriben, a selective delta2-opioid receptor antagonist, or 7-benzylidenenaltrexone. a selective delta1-opioid receptor antagonist.
17	10225369	Subcutaneous injection of 7-benzylidenenaltrexone (0.1, 0.3 and 1 mg/kg), an antagonist of delta1-opioid receptors, had no significant effect on either somatostatin-, bradykinin- or prostaglandin F2alpha-induced nociceptive responses in non-diabetic mice. 7-Benzylidenenaltrexone (0.1 and 0.3 mg/kg, s.c.) also had no significant effect on somatostatin- or prostaglandin F2alpha-induced nociceptive responses in diabetic mice.
18	10225369	These results suggest that a spinal delta1-opioid receptor-mediated endogenous antinociceptive system may inhibit the bradykinin-mediated nociceptive responses in the second phase of the formalin-induced nociceptive response in diabetic mice.
19	10225369	Subcutaneous injection of 7-benzylidenenaltrexone (0.1, 0.3 and 1 mg/kg), an antagonist of delta1-opioid receptors, had no significant effect on either somatostatin-, bradykinin- or prostaglandin F2alpha-induced nociceptive responses in non-diabetic mice. 7-Benzylidenenaltrexone (0.1 and 0.3 mg/kg, s.c.) also had no significant effect on somatostatin- or prostaglandin F2alpha-induced nociceptive responses in diabetic mice.
20	10225369	These results suggest that a spinal delta1-opioid receptor-mediated endogenous antinociceptive system may inhibit the bradykinin-mediated nociceptive responses in the second phase of the formalin-induced nociceptive response in diabetic mice.
21	11735084	Specific binding sites for [125I]beta-endorphin and the delta1-opioid [3H][D-pen(2), D-pen(5)]enkephalin (DPDPE) were quantified using autoradiography in soleus and extensor digitorum longus (EDL) muscles of lean and obese-diabetic (ob/ob) mice.
22	12398906	In non-diabetic mice, the antinociceptive effect of i.c.v. or i.t. administration of pinacidil was significantly antagonized by beta-funaltrexamine, a mu-opioid receptor antagonist, 7-benzylidenenaltrexone, a delta1-opioid receptor antagonist, naltriben, a delta2-opioid receptor antagonist, and nor-binaltorphimine, a kappa-opioid receptor antagonist.
23	12403815	The present study demonstrates that adult human pancreatic duct cells can be converted into insulin-expressing cells after ectopic, adenovirus-mediated expression of the class B basic helix-loop-helix factor neurogenin 3 (ngn3), which is a critical factor in embryogenesis of the mouse endocrine pancreas.
24	12403815	Infection with adenovirus ngn3 (Adngn3) induced gene and/or protein expression of NeuroD/beta2, Pax4, Nkx2.2, Pax6, and Nkx6.1, all known to be essential for beta-cell differentiation in mouse embryos.
25	12403815	Expression of ngn3 in adult human duct cells induced Notch ligands Dll1 and Dll4 and neuroendocrine- and beta-cell-specific markers: it increased the percentage of synaptophysin- and insulin-positive cells 15-fold in ngn3-infected versus control cells.
26	12403815	Infection with NeuroD/beta2 (a downstream target of ngn3) induced similar effects.
27	15850778	Using a much larger sample of T1D families than those studied by others, and by extensive re-sequencing of nine other genes in the proximity, in which we identified 279 polymorphisms, 83 of which were genotyped in up to 725 T1D multiplex and simplex families, we obtained no evidence for association of the TBP CAG/CAA (glutamine) microsatellite repeat sequence with disease, or for nine other genes, PDCD2, PSMB1, KIAA1838, DLL1, dJ894D12.4, FLJ25454, FLJ13162, FLJ11152, PHF10 and CCR6.
28	16313098	The selective delta1-opioid receptor antagonist 7-benzylidenenaltrexone (0.3 and 1 mg/kg/day, s.c.), but not the selective delta2-opioid receptor antagonist naltriben (0.3 and 1 mg/kg/day, s.c.), significantly reduced the escape latencies in diabetic mice.
29	16313098	The selective delta1-opioid receptor agonist [D-Pen2, D-Pen5]-enkephalin (10 nmol/mouse/day, i.c.v.) significantly increased the escape latencies in both non-diabetic and diabetic mice.
30	16313098	The selective delta1-opioid receptor antagonist 7-benzylidenenaltrexone (0.3 and 1 mg/kg/day, s.c.), but not the selective delta2-opioid receptor antagonist naltriben (0.3 and 1 mg/kg/day, s.c.), significantly reduced the escape latencies in diabetic mice.
31	16313098	The selective delta1-opioid receptor agonist [D-Pen2, D-Pen5]-enkephalin (10 nmol/mouse/day, i.c.v.) significantly increased the escape latencies in both non-diabetic and diabetic mice.
32	16945141	The region contains a number of potential candidate genes, including programmed cell death 2 (PDCD2), the proteosome subunit beta type 1 (PSMB1), delta-like ligand 1 (DLL-1) and TATA box-binding protein (TBP) amongst others.